1 min read
Chief Medical Officer Summit -CMO 360°
Meet the Veristat team at Booth #3, April 17th and 18th in Boston
The Science-First CRO™ and Consultancy Ready to...
2 min read
Latest Updates from FDA & EMA
March 2019
Each month, Veristat's regulatory team tracks and shares a selection of new Regulatory Guidance updates from the US Food & Drug Administration (FDA) and European Medicines Agency (EMA) that are pertinent to the governance of clinical trials and drug, biologic, or medical device development and approval. Below are the relevant links to updates provided in March 2019.
FDA Updates
FDA has finalized the following guidance documents:
Considerations for the Inclusion of Adolescent Patients in Adult Oncology Trials (finalized 03/12/2019)
https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM609513.pdf
Enrichment Strategies for Clinical Trials to Support Approval of Human Drugs and Biological Products (finalized 03/14/19)
https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM332181.pdf
Severely Debilitating or Life-Threatening Hematologic Disorders: Nonclinical Development of Pharmaceuticals (finalized 03/14/19)
https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM605393.pdf
Standards Development and the Use of Standards in Regulatory Submissions Reviewed in the Center for Biologics Evaluation and Research (finalized March 2019)
FDA has issued the following new draft guidance documents:
Bioavailability Studies Submitted in NDAs or INDs – General Considerations (issued 02/25/19)
https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM631943.pdf
Assessing the Effects of Food on Drugs in INDs and NDAs – Clinical Pharmacology Considerations (02/25/19)
https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM631941.pdf
Quality Considerations for Continuous Manufacturing (issued 02/26/19)
https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM632033.pdf
Cancer Clinical Trial Eligibility Criteria: Brain Metastases (issued 03/12/19)
https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM633132.pdf
Cancer Clinical Trial Eligibility Criteria: Patients with Organ Dysfunction or Prior or Concurrent Malignancies (03/12/19)
https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM633137.pdf
Cancer Clinical Trial Eligibility Criteria: Minimum Age for Pediatric Patients (03/12/19)
https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM633138.pdf
Cancer Clinical Trial Eligibility Criteria: Patients with HIV, Hepatitis B Virus, or Hepatitis C Virus Infections (03/12/19)
https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM633136.pdf
A Risk-Based Approach to Monitoring of Clinical Investigations Questions and Answers (03/14/19)
https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM633316.pdf
- This is an expansion of the 2013 guidance “Oversight of Clinical Investigations – A Risk-Based Approach to Monitoring”; it does not replace the 2013 guidance.
Rare Diseases: Natural History Studies for Drug Development (03/22/19)
https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM634062.pdf
Pediatric Information Incorporated Into Human Prescription Drug and Biological Product Labeling (03/27/19)
https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM341394.pdf
FDA In The News:
Statement from FDA Commissioner Scott Gottlieb, M.D., on new strategies to modernize clinical trials to advance precision medicine, patient protections and more efficient product development (03/14/19)
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm633500.htm
EMA Updates:
EMA has published a questions-and-answers (Q&A) document on the preparatory work that European Union authorities are doing to prevent medicine shortages due to the United Kingdom’s withdrawal from the EU. (03/26/19)
https://www.ema.europa.eu/en/news/questions-answers-eu-actions-prevent-medicine-shortages-due-brexit
As of today, EMA is operating from Amsterdam (03/11/19)
https://www.ema.europa.eu/en/news/ema-now-operating-amsterdam
New EudraVigilance system improves reporting of side effects and detection of safety signals (03/27/19)
- Regulatory Affairs
- Regulatory Consulting
- Regulatory Approvals
- Agency Meetings Support
- Regulatory Publishing